The specific BCL-2 small molecule inhibitor venetoclax induces apoptosis in a wide range of malignancies, which has led to rapid clinical expansion in its use alone and in combination with chemotherapy and immune-based therapies against a myriad of cancer types. While lymphocytes, and T cells in particular, rely heavily on BCL-2 for survival and function, the effects of small molecule blockade of the BCL-2 family on surviving immune cells is not fully understood. We aimed to better understand the effect of systemic treatment with venetoclax on regulatory T cells (Treg), which are relatively resistant to cell death induced by specific drugging of BCL-2 compared to other T cells. We found that BCL-2 blockade altered Treg transcriptional profiles and mediated Treg plasticity toward a TH17-like Treg phenotype, resulting in increased IL17A production in lymphoid organs and within the tumor microenvironment. Aligned with previously described augmented antitumor effects observed when combining venetoclax with anti–PD-1 checkpoint inhibition, we also demonstrated that Treg-specific genetic BCL-2 knockout combined with anti–PD-1 induced tumor regression and conferred overlapping genetic changes with venetoclax-treated Tregs. As long-term combination therapies using venetoclax gain more traction in the clinic, an improved understanding of the immune-modulatory effects caused by venetoclax may allow expansion of its use against malignancies and immune-related diseases.
Supplementary Figure S10. Percentage of RORγt+ Tregs in the (A) spleens (B) draining lymph nodes, and (C) tumors of Foxp3eGFP-Cre-ERT2 Bcl2fl/fl 7 days into treatment as shown in Fig. 7. Data represented as means ± SD. *p < 0.05, **p <0.01, ***p < 0.001.
Supplementary Figure S5. Differential accessibility of key transcription factors that have shown to play a role in Treg plasticity represented in Tregs isolated from vehicle and venetoclaxtreated animals. Specifically, increased accessibility of RORγt, BATF, and IRF4 are crucial for Treg to TH17 plasticity.